Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

Bioequivalence Clinical Trial

Official title:

Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Oseltamivir Phosphate 75 mg Capsule of Yangtze River Pharmaceutical (Group) Co., Ltd., China and TAMIFLU® (Oseltamivir Phosphate) Capsules 75 mg of Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990 in Healthy, Adult, Human Subjects Under Fed Condition

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04536415
• Other study ID #: 20-VIN-0051
• Status: Completed
• Phase: Phase 4
• Start date: August 25, 2020
• Est. completion date: August 27, 2020

Study information

• Verified date: February 2023
• Source: Austarpharma, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the bioequivalence of Oseltamivir Phosphate Capsules 75 mg versus TAMIFLU 75 mg capsules administered as 75 mg capsules in healthy volunteers under Fed condition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: August 27, 2020
• Est. primary completion date: August 27, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Subjects' weight within normal range according to normal values for Body Mass Index (18.50 to 30.00 kg/m2) with minimum of 50 kg weight.

• Subjects with Hemoglobin level = 11.5 G% at the time of screening.

• Subjects with normal health as determined by personal medical and medication history, clinical examination and laboratory examinations within the clinically acceptable normal range.

• Subjects having clinically acceptable 12-lead electrocardiogram (ECG).

• Subjects having clinically acceptable chest X-Ray (PA view).

• Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

• Subjects having negative alcohol breath test or urine alcohol test.

• Subjects willing to adhere to the protocol requirements and to provide written informed consent.

• For Male Subjects: Subjects willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide ,Condom with diaphragm , or abstinence, subjects should also not donate sperm during this time.

• Subjects having negative urine pregnancy test at screening and negative Serum ß-hCG pregnancy test on admission day of period 01 (only for female subjects).

• For Female Subjects: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), or abstinence or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam; or Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above; Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).

Exclusion Criteria:

• Hypersensitivity to Oseltamivir or related class of drugs or any of its excipients or to heparin.

• History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.

• Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to dosing of period 01.

• Presence of significant alcoholism or drug abuse.

• History or presence of significant smoking (more than 10 cigarettes or beedis/day).

• History or presence of asthma, urticaria or other significant allergic reactions.

• History or presence of significant gastric and/or duodenal ulceration or gastrointestinal (GI) bleeding.

• History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.

• History or presence of cancer or basal or squamous cell carcinoma.

• Difficulty with donating blood.

• Difficulty in swallowing solids like tablets or capsules.

• Use of any prescribed medication or OTC medication within 30 days prior to dosing in period 01.

• Major illness within past 3 months.

• Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.

• Consumption of xanthine-containing products, tobacco containing products or alcohol within 48 hours prior to dosing of period 01.

• Consumption of grapefruit or grapefruit juice containing products within 72 hours prior to dosing of period 01.

• Positive screening test result for any one or more: HIV, Hepatitis B and Hepatitis C.

• History or presence of significant easy bruising or bleeding.

• History or presence of significant recent trauma.

• Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.

• Female subjects who are currently breast feeding.

Related Conditions & MeSH terms

• Bioequivalence
• Malnutrition

Intervention

Drug:
• Oseltamivir Phosphate 75 mg capsules
Capsules, 75 mg, single, oral dose
• Tamiflu capsules 75 mg
Capsules, 75 mg, single, oral dose

Locations

Country	Name	City	State
United States	Austarpharma Llc	Edison	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Austarpharma, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax)	Maximum measured concentration over the time span specified	48 hours
Primary	Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]	The area under the concentration versus time curve, from time 0 to the last measurable concentration, where t = time of last measurable concentration, calculated using linear trapezoidal method	48 hours
Primary	Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC)	The area under the concentration versus time curve from time 0 to infinity AUC0-8 = AUC0-t + Clast/Kel; where Clast is last measurable concentration, Kel is elimination rate constant.	48 hours